Human Metabolome Technologies, Inc.
Tokyo Stock Exchange 6090.T
Human Metabolome Technologies, Inc. Cash and Short-Term Investments for the year ending June 30, 2024: USD 11.14 M
-
Human Metabolome Technologies, Inc. Cash and Short-Term Investments for the year ending June 30, 2023 was USD 11.48 M, a 3.59% change year over year.
-
Human Metabolome Technologies, Inc. Cash and Short-Term Investments for the year ending June 30, 2022 was USD 11.08 M, a -1.11% change year over year.
-
Human Metabolome Technologies, Inc. Cash and Short-Term Investments for the year ending June 30, 2021 was USD 11.21 M, a -0.74% change year over year.
-
Human Metabolome Technologies, Inc. Cash and Short-Term Investments for the year ending June 30, 2020 was USD 11.29 M.
| Date | Cash and Short-Term Investments | Receivables | Inventory | Goodwill |
|---|
Don’t Miss A Beat
| CEO | Mr. Yasuhiro Ohata |
| IPO Date | Jan. 21, 2014 |
| Location | Japan |
| Headquarters | 246-2 Mizukami Kakuganji |
| Employees | 58 |
| Sector | Health Care |
| Industries | |
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
Past 5 years
StockViz Staff
January 31, 2025
Any question? Send us an email